Combined GHRP-2 + GHRH Sustainably Elevates GH and IGF-1 in Healthy Older Adults

Combined subcutaneous GHRP-2 + GHRH infusion sustained pulsatile GH secretion and elevated IGF-1 and IGFBP-3 in healthy older adults with gender-specific synergy — women showed greater response than men.

Bowers, Cyril Y et al.·The Journal of clinical endocrinology and metabolism·2004·Strong Evidenceclinical-trial
RPEP-00887Clinical TrialStrong Evidence2004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Combined SC GHRP-2 + GHRH infusion sustainably elevated pulsatile GH, IGF-1, and IGFBP-3 in healthy older adults without desensitization, with synergy exceeding individual effects and women showing greater response than men.

Key Numbers

How They Did This

Clinical trial in healthy older adults. SC infusion of combined GHRP-2 + GHRH. GH profiling (deconvolution analysis), IGF-1, IGFBP-3 measured. Gender comparison. Synergy versus individual peptide effects assessed.

Why This Research Matters

Age-related GH decline affects millions. A sustained, synergistic peptide combination that restores youthful GH patterns without desensitization could transform anti-aging endocrinology.

The Bigger Picture

The combination of GHRP + GHRH is the most effective physiological approach to restoring GH secretion in aging — hitting both the accelerator and releasing the brake simultaneously.

What This Study Doesn't Tell Us

Short-term SC infusion study. Long-term chronic infusion effects need assessment. SC infusion is less practical than oral or daily injection dosing.

Questions This Raises

  • ?Can the synergistic effect be achieved with intermittent dosing?
  • ?Why do women respond more than men?
  • ?Could this combination prevent age-related muscle and bone loss?

Trust & Context

Key Stat:
Sustained without fade Combined GHRP-2 + GHRH maintained elevated pulsatile GH and IGF-1 without desensitization in older adults — sustainable anti-aging hormone restoration
Evidence Grade:
Strong evidence from a well-designed clinical trial with intensive hormonal profiling and gender comparison in the target elderly population.
Study Age:
Published in 2004. Combined GHRP + GHRH remains the gold standard for research on restoring the aging GH axis.
Original Title:
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
Published In:
The Journal of clinical endocrinology and metabolism, 89(5), 2290-300 (2004)
Database ID:
RPEP-00887

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can GH decline with aging be reversed?

This study shows combined GHRP-2 + GHRH sustainably restores youthful GH secretion patterns in older adults — without the response fading over time. It's the most effective approach tested for aging GH restoration.

Do men and women respond differently?

Yes — women showed greater GH response to the combination. This gender difference is important for dosing and may relate to estrogen's protective effects on the GH axis.

Read More on RethinkPeptides

Cite This Study

RPEP-00887·https://rethinkpeptides.com/research/RPEP-00887

APA

Bowers, Cyril Y; Granda, Ramona; Mohan, Subburaman; Kuipers, Jonathan; Baylink, David; Veldhuis, Johannes D. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.. The Journal of clinical endocrinology and metabolism, 89(5), 2290-300.

MLA

Bowers, Cyril Y, et al. "Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.." The Journal of clinical endocrinology and metabolism, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Sustained elevation of pulsatile growth hormone (GH) secreti..." RPEP-00887. Retrieved from https://rethinkpeptides.com/research/bowers-2004-sustained-elevation-of-pulsatile

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.